{"id":17925,"date":"2024-04-09T17:02:27","date_gmt":"2024-04-09T17:02:27","guid":{"rendered":"https:\/\/allonlinebanglanewspapers.com\/news\/excessive-daytime-sleepiness-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2032-predicts-delveinsight-key-companies-in-the-market-avadel-pharmaceutical-axsome-therapeutic-theranexus\/"},"modified":"2024-04-09T17:02:27","modified_gmt":"2024-04-09T17:02:27","slug":"excessive-daytime-sleepiness-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2032-predicts-delveinsight-key-companies-in-the-market-avadel-pharmaceutical-axsome-therapeutic-theranexus","status":"publish","type":"post","link":"https:\/\/allonlinebanglanewspapers.com\/news\/excessive-daytime-sleepiness-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2032-predicts-delveinsight-key-companies-in-the-market-avadel-pharmaceutical-axsome-therapeutic-theranexus\/","title":{"rendered":"Excessive Daytime Sleepiness Market is Projected to Boost at a Moderate Growth Rate by 2032, Predicts DelveInsight | Key Companies in the Market &#8211; Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, XWPharma, Takeda Pharmaceutical"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<p align=\"justify\">New York, USA, April  09, 2024  (GLOBE NEWSWIRE) &#8212; <strong>Excessive Daytime Sleepiness Market is Projected to Boost at a Moderate Growth Rate by 2032, Predicts DelveInsight | Key Companies in the Market &#8211; Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, XWPharma, Takeda Pharmaceutical<\/strong><\/p>\n<p align=\"justify\"><strong><em>The excessive daytime sleepiness market is expected to grow due to factors like an increase in the patient population due to a rise in the prevalence of underlying medical conditions, expected entry of emerging therapies in the coming years.<\/em><\/strong><\/p>\n<p align=\"justify\">DelveInsight\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=li7FF3V74vXXM0QVPlBhLq6RQYO7yUVltJEAkeinhk2nlorJcp0ONYxU0scBrt2teG5aszaUtG0YM_jRHxgJNlcU8c8uDXiS3C8HDKhmqxV8OhIL01UImZu2fYYTKYUOCPj9mVGccM33Uzx5_GZRqFvkErK0iTyLCqfDxnXUS3iSbbN60bmL983iqde3yv2PzYAHZ2QCMKDck1pbK3c9YIvIsLJHuYs0-Cp5YzjMyJxRbMUG9SYoTkfTyzx7_vuBGaVfs2AhFYa8uTb0m1bUQgbqedp2LeaznOsOHFfA7Iw=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Excessive Daytime Sleepiness Market Insights<\/strong><\/a> report includes a comprehensive understanding of current treatment practices, excessive daytime sleepiness emerging drugs, market share of individual therapies, and current and forecasted excessive daytime sleepiness market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].<\/p>\n<p align=\"justify\"><strong>Key Takeaways from the Excessive Daytime Sleepiness Market Report<\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">According to DelveInsight\u2019s analysis, the market size for excessive daytime sleepiness reached <strong>USD 5 billion<\/strong> in 2021 across the 7MM and is expected to grow with a significant CAGR by 2032.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">DelveInsight\u2019s analysis reveals that the overall diagnosed prevalent population of excessive daytime sleepiness in the 7MM was reported as <strong>6.8<\/strong> <strong>million<\/strong> in 2021.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Prominent companies working in the domain of excessive daytime sleepiness, including <strong>Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, Suven Life Sciences, NLS Pharma Ltd, XWPharma, Takeda Pharmaceutical<\/strong>, and others, are actively working on innovative drugs for excessive daytime sleepiness. These novel excessive daytime sleepiness therapies are anticipated to enter the excessive daytime sleepiness market in the forecast period and are expected to change the market.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Some of the key therapies for excessive daytime sleepiness treatment include <strong>FT218 (Sodium Oxybate), AXS-12 (Reboxetine), THN102 (Flecainide and Modafinil), Samelisant (SUVN-G3031), Quilience (Mazindol Extended-release\/NLS-2), XW10172, TAK-994<\/strong><strong>, <\/strong>and others.\u00a0<\/li>\n<\/ul>\n<p align=\"justify\">Discover which therapies are expected to grab the excessive daytime sleepiness market share @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=li7FF3V74vXXM0QVPlBhLq6RQYO7yUVltJEAkeinhk01I3kD5k2tBuV06dr44UE04fkEkWoCbJnbME2Hj6AjEwJ51INg8oUVUJYZ3nmBoC7gxwUqvqDdEyCE6SkFpGJjyK-IkFt474l4t2B7MWkmIem6-z3biL0gwvaAdtJJwGfcBn1PRftTSfiRkVtGhzEa6aK6tbEz1UDKgLON0oeQVta7mtCSjHpfOqZVRJXGNMKeUzN2R6o_jI59flfDmItyxeXLCRnAEGFl-Yy4U6LLOk7fQ7W0B1ty-7GYXdnXLJY=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Excessive Daytime Sleepiness Market Report<\/strong><\/a><\/p>\n<p align=\"justify\"><strong>Excessive Daytime Sleepiness Overview<\/strong><\/p>\n<p align=\"justify\">Excessive daytime sleepiness (EDS) is characterized by a challenge in remaining awake and attentive during the primary waking periods of the day, resulting in unintentional or untimely sleep. EDS is frequently linked to various health conditions such as metabolic, cardiovascular, neurological, and psychiatric diseases, as well as lifestyle choices indicative of insufficient or poor-quality sleep. This can lead to disability and an elevated risk of mortality. Identifying EDS in children may be more challenging, as its manifestations can differ from those in adults. Older children might resume taking naps, while younger ones may extend their daytime or nighttime sleep. If an individual consistently experiences drowsiness throughout the day, leading to untimely and inconvenient episodes of falling asleep, negatively impacting productivity, it is advisable to seek advice from a healthcare professional. The diagnosis of EDS involves utilizing questionnaires, identifying any underlying medical conditions, and employing diagnostic tests such as the Epworth Sleepiness Scale (ESS), Multiple Sleep Latency Test (MSLT), and Maintenance of Wakefulness Test (MWT).<\/p>\n<p><\/p>\n<p align=\"justify\"><strong>Excessive Daytime Sleepiness Epidemiology Segmentation<\/strong><\/p>\n<p align=\"justify\">The excessive daytime sleepiness epidemiology section provides insights into the historical and current excessive daytime sleepiness patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.<\/p>\n<p align=\"justify\">The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=woXfRdPJFTu5vLuQo2lVNeusvK1yNgGXh9BDnQ5rxOIfFRs5pOYZOihBg5hVI9LFdRV2oNLkouqg3ejlU1h2GYaNPS5s6gFI2YLOhNYZgjEOMhcp_vRyBPoUqsxdZdIw8YX_5gHsjO7aC9SLC1ruo5gS7UeiRMdmnM-ZfWFdLOKWeZ6wPPhSFO3srXSyaW4kDtgbQ-DayyFk9DYbGV2EZy0Ea1_xpcZ3Ck81ts_beYyRJupuz3nnksPsNlINHenPmu0lslqqZXFsmg_5N5us-4nDOyV8_MH9wqr9QftQ4gI=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>excessive daytime sleepiness market report<\/strong><\/a> proffers epidemiological analysis for the study period 2019\u20132032 in the 7MM segmented into:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">Total Diagnosed Prevalent Cases of EDS<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Total Diagnosed Prevalent Cases of EDS in Different Disorder<\/li>\n<\/ul>\n<p align=\"justify\">Download the report to understand which factors are driving excessive daytime sleepiness epidemiology trends @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=li7FF3V74vXXM0QVPlBhLq6RQYO7yUVltJEAkeinhk1zq3HkMDz8wNgYpvcjc2pDzcoAPg6pxzlbF_0m6dANlGMFqJrbqUP0ykJzf0pZEI_NLpqDZifhjmaoxZgUIHUoZ3Gyd-7iL0STGft6tPafdWTeQEeOJfYo2Dcj-yQsxRbU2MxfkEKVOYyIJ_u5ZtpL02UGkLj917fqpDEnTwqz98ntrnKILRy_d83-Kl8NkY-vUqGsDBeQL_Xn59E0Fl6JNLC-3GCRDmUhu8XNwec1LKQRjBWaAhVUez7sgN3TEilqos5SQ0hY_nmi_U4tZ9FQ\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Excessive Daytime Sleepiness Epidemiological Insights<\/strong><\/a><\/p>\n<p align=\"justify\"><strong>Excessive Daytime Sleepiness Treatment Market\u00a0<\/strong><\/p>\n<p align=\"justify\">Excessive daytime sleepiness is commonly addressed through the administration of central nervous system stimulants resembling amphetamines, such as <strong>methylphenidate or modafinil<\/strong>, along with its <strong>R-enantiomer, armodafinil<\/strong>. These compounds, which promote wakefulness, are distinct from traditional amphetamines. Recently, the American Academy of Sleep Medicine (AASM) has advocated for <strong>sodium oxybate<\/strong>, a brief-acting sedative with unknown mechanisms, as the primary treatment for EDS and cataplexy. The prevalent amphetamine-like substances include <strong>methylphenidate, methamphetamine, D-amphetamine<\/strong> (all categorized as schedule II compounds), and <strong>mazindol <\/strong>(classified as a schedule IV compound). The utilization of stimulants in narcolepsy has often been addressed through practice standards outlined by the AASM.<\/p>\n<p align=\"justify\">Usually, a person is initiated on a modest dosage and gradually escalated to achieve desired outcomes. Initial trials often involve less potent stimulants like modafinil or armodafinil. If necessary, more potent amphetamine-like stimulants such as methylphenidate, D-amphetamine, and methamphetamine may be introduced. In individuals with narcolepsy, stimulant compounds are typically well received.<\/p>\n<p align=\"justify\">In the 7MM, only a limited number of drugs have received approval for treating EDS. These include <strong>Provigil\/Modiodal (modafinil), Nuvigil (armodafinil), Sunosi (solriamfetol), Wakix (Pitolisant), Xywav (calcium, magnesium, potassium, and sodium oxybates), and Xyrem (sodium oxybate). Generic versions of Provigil\/Modiodal (modafinil) and Nuvigil (armodafinil)<\/strong> are currently available in the US excessive daytime sleepiness treatment market.<\/p>\n<p align=\"justify\">Learn more about the FDA-approved drugs for excessive daytime sleepiness @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IJP54Fymdl3zZfNfAS27viCz69V_2p83ehRmBdrKW5Ju9Aqv2lAqP7fxpuNF7DJKV9Sf8cpE7cgJvFDyP1BvxJtJ233scThIWmuv6SFPVRWUMs9fslvSXxaBo5ivxZ4vQIeTZRuK-rcHeb867b2boDSZWO6OgUFjI-zbw3mpgiNeiL80_wPJRyjEKWDwqQpetHcMqWZx58-KGH2aB8qrHDe57U3Y5Fh5TtFs0piVP4Ckbsw6kcAyemwKibkw_P4t-Yxv9TY8eCv-R0nYjDXNHRzzO3Hpv_HW65LhaoyWb7I=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Drugs for<\/strong> <strong>Excessive Daytime Sleepiness Treatment<\/strong><\/a><strong>\u00a0<\/strong><\/p>\n<p align=\"justify\"><strong>Excessive Daytime Sleepiness Emerging Drugs and Companies<\/strong><\/p>\n<p align=\"justify\">Companies across the globe are diligently working toward the development of novel therapies for EDS with a considerable amount of success over the years. Key players, such as <strong>Avadel Pharmaceuticals (FT218), Axsome Therapeutics (AXS-12)<\/strong>, and others, are developing therapies for the treatment of EDS.<\/p>\n<p align=\"justify\"><strong>Avadel&#8217;s FT218<\/strong> is a new form of sodium oxybate under investigation. It utilizes a unique micropump technology to deliver an extended-release oral suspension, designed to be taken once at night. This formulation aims to address excessive daytime sleepiness (EDS) and cataplexy in individuals with narcolepsy. Sodium oxybate is already approved for treating EDS and cataplexy in narcolepsy patients.<\/p>\n<p align=\"justify\"><strong>AXS-12 (reboxetine)<\/strong> is a potent and highly specific inhibitor of norepinephrine reuptake currently being researched for narcolepsy therapy. It regulates noradrenaline function to improve alertness, muscle tone, and cognitive functions. Reboxetine has a well-documented safety profile across Europe and more than 40 countries where it&#8217;s authorized for treating depression.<\/p>\n<p align=\"justify\">Some of the other therapies in the EDS pipeline include<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">THN102 (Flecainide and Modafinil): Theranexus<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Samelisant (SUVN-G3031): Suven Life Sciences<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Quilience (Mazindol Extended-release\/NLS-2): NLS Pharma Ltd<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">XW10172: XWPharma<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">TAK-994: Takeda Pharmaceutical<\/li>\n<\/ul>\n<p align=\"justify\">As these therapies progress through clinical trials and gain regulatory approval, they are expected to capture significant market share, challenging established medications and driving innovation in sleep medicine. Moreover, with growing awareness and acceptance of sleep disorders as legitimate medical conditions, the demand for effective treatments is likely to soar, further fueling the expansion of this evolving market landscape.<\/p>\n<p align=\"justify\">To know more about excessive daytime sleepiness clinical trials, visit @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=li7FF3V74vXXM0QVPlBhLq6RQYO7yUVltJEAkeinhk0WmyWMoYEbR9oyTWT6pe1mB0NM6XN7c_xxMjoWpBr3KdMdNQNMfr1a4ASQCx8YM2zHQSASul__qtiZeRFMlXdTB733v5bD_ZgsQrO45oXjQuJjQQvAVAHcKgZUgYspABbm_gV5xNqrflVloFpK_DxmnvtFnCXzQVoGoQkP0mvVrCW-5ilxCzze8tGW_fGDnHgxMOfA0lEurMf58FwUe4_PkvRYz97KLfn0HXGl2hkT3JVNCTQOQ6FuSvwbUbyMS34=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Excessive Daytime Sleepiness Treatment Drugs<\/strong><\/a><strong>\u00a0<\/strong><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=li7FF3V74vXXM0QVPlBhLq6RQYO7yUVltJEAkeinhk3u1mtoYWs69AzssjkccTgIXD11kgMNkgnBLEn2L5vS9fr_TibZQw0iF_fNqoQcLFYA7UJo-DTBA9CT8x761l95DbIUY30EAQbkdr9w8zTa4C68iDkMgcPqw_d3BO4BGKG1_1-ZVelJOzrEirC4e17Q5b5Je32tXWfxFXrP8ZFV0X7DhQVXJuWWdWi7L7aN7I3KmiHiZWMRO7Vw_3NmP3MpdFB93o9jN33w3xFiXoSl-10ZaEll_y7Fj5VA80B8Z0A=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Excessive Daytime Sleepiness Market Dynamics<\/strong><\/a><\/p>\n<p align=\"justify\">The excessive daytime sleepiness market dynamics are anticipated to change in the coming years. The <strong>growing occurrence of related conditions<\/strong> like Parkinson&#8217;s disease, OSA, narcolepsy, etc., could lead to a rise in the number of individuals with EDS. The approval of <strong>Ozawade (pitolisant)<\/strong> in Europe and the acceptance of the IND application in the US for idiopathic hypersomnia are anticipated to bolster the EDS market. A notable challenge is the insufficient focus on <strong>research and development<\/strong> for innovative mechanisms of action. The majority of approved therapies are <strong>designed for daily use<\/strong>, emphasizing the existing gap in the excessive daytime sleepiness market for medications with prolonged effectiveness.<\/p>\n<p align=\"justify\">Furthermore, many potential therapies are being investigated for the treatment of excessive daytime sleepiness, and it is safe to predict that the treatment space will significantly impact the excessive daytime sleepiness market during the forecast period. Moreover, the <strong>anticipated introduction of emerging therapies<\/strong> with improved efficacy and a further <strong>improvement in the diagnosis rate<\/strong> are expected to drive the growth of the excessive daytime sleepiness market in the 7MM.<\/p>\n<p align=\"justify\">However, several factors may impede the growth of the excessive daytime sleepiness market. <strong>Limited awareness<\/strong> of certain related diseases, such as bipolar disorder, remains unaddressed, potentially hindering excessive daytime sleepiness market growth. In addition, the excessive daytime sleepiness market is anticipated to see the <strong>introduction of generic versions of Sunosi<\/strong> in 2026.<\/p>\n<p align=\"justify\">Moreover, excessive daytime sleepiness treatment poses a <strong>significant economic burden<\/strong> and disrupts patients\u2019 overall well-being and QOL. Furthermore, the excessive daytime sleepiness market growth may be offset by <strong>failures and discontinuation of emerging therapies<\/strong>, <strong>unaffordable pricing<\/strong>, <strong>market access and reimbursement issues<\/strong>, and a <strong>shortage of healthcare specialists<\/strong>. In addition, the <strong>undiagnosed, unreported cases and the unawareness<\/strong> about the disease may also impact the excessive daytime sleepiness market growth.<\/p>\n<table style=\"border-collapse: collapse; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><strong>Excessive Daytime Sleepiness Report Metrics<\/strong><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><strong>Details<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Study Period<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">2019\u20132032<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Excessive Daytime Sleepiness Report Coverage<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Excessive Daytime Sleepiness Market Size in 2021<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">USD 5 Billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Excessive Daytime Sleepiness Companies<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, Suven Life Sciences, NLS Pharma Ltd, XWPharma, Takeda Pharmaceutical, and others<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Excessive Daytime Sleepiness Therapies<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">FT218 (Sodium Oxybate), AXS-12 (Reboxetine), THN102 (Flecainide and Modafinil), Samelisant (SUVN-G3031), Quilience (Mazindol Extended-release\/NLS-2), XW10172, TAK-994, and others<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><strong>Scope of the <\/strong><strong>Excessive Daytime Sleepiness<\/strong><strong> Market Report<\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\"><strong>Excessive Daytime Sleepiness Therapeutic Assessment: <\/strong>Excessive Daytime Sleepiness current marketed and emerging therapies<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><strong>Excessive Daytime Sleepiness<\/strong> <strong>Market Dynamics:<\/strong> Attribute Analysis of Emerging Excessive Daytime Sleepiness Drugs<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis and Market entry strategies<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><strong>Unmet Needs, KOL\u2019s views, Analyst\u2019s views, Excessive Daytime Sleepiness Market Access and Reimbursement<\/strong><\/li>\n<\/ul>\n<p align=\"justify\">Discover more about excessive daytime sleepiness drugs in development @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=li7FF3V74vXXM0QVPlBhLq6RQYO7yUVltJEAkeinhk3xXbXJLKK0l9BIzWkFJVdu9-xEixaZo0HLqt5lhtyzsHkUGSh0HQ9m26pZiSgWvRV2NyL3GvDd_2dtPWCQELOgkCdvrDNJODLpT2yDJiWrNjtqsiJ_jvPMM1Jnb0TZeyXNcF_ThTSvCB7fV-QMGZ_1Dz6nK-PfEDJeTv9-Ge_FNgJTNBWoDO2u1XITbFLDDsB8l3EDHut2QQWWg3Yxh6v4_qFMBmwo1PQW644lqcAL_bwHEhBh5ttpp9NmCHBILZk=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Excessive Daytime Sleepiness Clinical Trials<\/strong><\/a><\/p>\n<p align=\"justify\"><strong>Table of Contents<\/strong><\/p>\n<table style=\"border-collapse: collapse; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">1.<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Excessive Daytime Sleepiness Market Key Insights<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">2.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Excessive Daytime Sleepiness Market Report Introduction<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">3.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Excessive Daytime Sleepiness Market Overview at a Glance<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">4.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Excessive Daytime Sleepiness Market Executive Summary<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">5.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Disease Background and Overview<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">6.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Excessive Daytime Sleepiness Treatment and Management<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">7.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Excessive Daytime Sleepiness Epidemiology and Patient Population<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">8.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Patient Journey<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">9.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Excessive Daytime Sleepiness Marketed Drugs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">10.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Excessive Daytime Sleepiness Emerging Drugs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">11.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Seven Major Excessive Daytime Sleepiness Market Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">12.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Excessive Daytime Sleepiness Market Outlook<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">13.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Potential of Current and Emerging Therapies<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">14.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">KOL Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">15.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Unmet Needs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">16.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">SWOT Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">17.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Appendix<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">18.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">DelveInsight Capabilities<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">19.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Disclaimer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">20.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">About DelveInsight<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><strong>Related Reports<\/strong><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=li7FF3V74vXXM0QVPlBhLq6RQYO7yUVltJEAkeinhk1zq3HkMDz8wNgYpvcjc2pD0UjSgQvDxsvnNnBNp_SFl0H-JOL6SQWGDVT6AWYFdFrIhzj97l3e_vtHxezhSI1Ohs1p5CI7wl3VN57nUHOWImQIsVsC1qC_9z5kZ42fBISUnk2uXYV3lb8--kCBDx45d-Ar2t6KxHNTSU9KT1QjV38Ls-HVVNBN8g_piUX6l-mGdPWd77QwmKwD7ieONMOdbt2l7WDgm0A3CHVXuX-YkWZhzl7_iFzUrV4OQLLhRC4OuC2cS8QA_k7553W0xMg2\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Excessive Daytime Sleepiness Epidemiology Forecast<\/strong><\/a><\/p>\n<p align=\"justify\"><strong>Excessive Daytime Sleepiness Epidemiology Forecast \u2013 2032<\/strong> report delivers an in-depth understanding of the disease, historical and forecasted excessive daytime sleepiness epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=li7FF3V74vXXM0QVPlBhLq6RQYO7yUVltJEAkeinhk1wPctxZWbPKPbg1BDAJ7IK3kjpOG6vkzt2ylmNm5EmUlZ8H6VPLkntP2xcO00FVA24nDyCapSEd1fXcTbp4fwPG1aQLg0CUvqbXwisuQ6uvbc6gbjm2X5BUPD98C0wS5nY-BUXnbRYbYgYEn0Rp0_YHizdoMwkAUHO_QLDDzoZal_LKx7EiMU4vpnJOxND1RWTISoGYemdk0Ys7OAQNcfoFXdYXwPelMoxfWwmhsevke7w5j72PH9M8IQ_29FMijo=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Excessive Daytime Sleepiness Pipeline<\/strong><\/a><\/p>\n<p align=\"justify\"><strong>Excessive Daytime Sleepiness Pipeline Insight <\/strong><strong>\u2013 2024<\/strong> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key excessive daytime sleepiness companies, including <strong>Balance Therapeutics, Takeda Pharmaceuticals, Benevolent AI Bio, Avadel Pharmaceuticals, Axsome Therapeutics,\u00a0 <\/strong>among others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BFfVC_0kkFRXYqkk_D5rPPdfx00n3jWqKUzc8bL3vqUYr8OQORMCbjrVkosgYBJAvu4F0h2dgr83V6rM4bH-F_9s6YFlHwVgMx-NjtjXh78RKjEPdUcMlV2Ak_G9bdjvc7Ne4P21BztLmXzEhtW8_K--zKD_vLJbq2EMW_X19c5XL4lt73NvUYIPss5x6CqWgJhcTqGVucRFFcnotG63n1fgIaJUdw1YmCYuaTZyWty3DaoiIg1VapwDk53Nuz0vl9zZ0zo8Pi0wynXSpEZNiQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Obstructive Sleep Apnea Market<\/strong><\/a><\/p>\n<p align=\"justify\"><strong>Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast \u2013 2032 <\/strong>report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key OSA companies, including <strong>Apnimed, Eli Lilly and Company<\/strong><strong>,<\/strong> among others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X_n7TKpPFgUgcRHxwlh38ISR9OiEwb6IRqGpb_SJ_wh-7DeC8qyOUj1NTFyDxOdPW2IYaBuYSjcK0sGV5Z2zTpUi_u17A_bkR35lX1sO2epfGuC9dIOk4OSwjQ1vXKW2-YxHdwGQQqarPcwdPytURktMlZt2Q8_HXD9Lnbm1JTh1uku9jzDyjEpdFUl5WvohkD5glfwTMLJHvcb9zXyU7fdpRs0paii2C9sziiAUOeU=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Sleep Aid Market<\/strong><\/a><\/p>\n<p align=\"justify\"><strong>Sleep Aid Market Insights, Competitive Landscape, and Market Forecast \u2013 2028 <\/strong>report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key sleep aid companies, including <strong>Pfizer Inc., Idorsia Pharmaceuticals Ltd., Eisai Co., Ltd., Jazz Pharmaceuticals, Harmony Biosciences, Otsuka Holdings Co., Ltd., Procter &amp; Gamble, Arlak Biotech Pvt. Ltd., Lumiera Health Inc, VedaOils, Forest Essentials, Neurim Pharmaceuticals LTD,<\/strong> among others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X_n7TKpPFgUgcRHxwlh38Dg2lZErw6nj59orebRgl8g7AbT5MnnugGtOR96tRX1kFp8BONKfEaubKS7GZhdF5BHLDdZSdBDuK9PmV0ZksrGaKHMpttoZaPXcAReHAiJFgMkizd6ohtZhJXfahuhKKBUkIdtZUoHeST1LfbPkt_C0_fm2tzO2YYWnqlf_n9yrAd9Dd7EbbU_Xgc-uZIw5I8rcvYVWmqZUDaZRxhsUBthJ5hACDnl1DOqBW7mk3gKg\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Sleep Tech Devices Market<\/strong><\/a><\/p>\n<p align=\"justify\"><strong>Sleep Tech Devices Market Insights, Competitive Landscape, and Market Forecast \u2013 2028 <\/strong>report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key sleep tech devices companies, including <strong>Koninklijke Philips N.V, Huawei Device Co Ltd., ResMed, Xiaomi, Apple Inc., Emfit Corp., Masimo, Garmin Ltd., Compumedics Limited, NIHON KOHDEN CORPORATION, Cadwell Industries Inc., Eight Sleep, Oura Health Oy, Sleep Shepherd LLC, Sleepace, Apollo Neuroscience Inc., Braebon Medical Corporation, Belun Technology, Nyxoah, Somnology, Inc.,<\/strong> among others.<\/p>\n<p align=\"justify\"><strong>About\u00a0DelveInsight<\/strong><\/p>\n<p align=\"justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve<strong>.<\/strong><\/p>\n<p align=\"justify\"><strong>Connect with us on<\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q9B9J-EgKypetdOke8HuItYRNNpyNB0xU52XEgZ3Xds8STV_WXQkY93LvKTrxAFEbujdLYha2-wZ-SEbRgdOf2S6IQ_bxoY4OXNO9n3a4-SAIZcrJBzpyXyrRq0AETSsW4YpmcxtCrYnVtcqu_mpqg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"> <strong>LinkedIn<\/strong><\/a><strong>|<\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bSqK1_JZ6-ICdqXO6EInqSVkJhRKiKWQ4V1Utc6wiP5yobN3n0mkaaJH4t-0ysX4sjY1FNHTt0IsRKP-uRQKvu6Hctzfk-JPF6-G8OElYGc=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Facebook<\/strong><\/a><strong>|<\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MjO_OYGJ8EwD7Q_f9npq9ELmSoQBwLyYEcFvV2amQtOJ-NK8EQ1ljfCPAF_AGSjPiGplcRKb13zT8om2ESoiinBzd3uci88IBbtHiYjz5ec=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Twitter<\/strong><\/a><\/p>\n<pre\/><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MTk4MGYxZGMtZTA1OC00NjBkLThhODYtNGFmNWY1NWRlNTFjLTEyMDQ5Mzg=\/tiny\/DelveInsight-Business-Research.png\" referrerpolicy=\"no-referrer-when-downgrade\"\/>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>New York, USA, April 09, 2024 (GLOBE NEWSWIRE) &#8212; Excessive Daytime Sleepiness Market is Projected to Boost at a Moderate Growth Rate by 2032, Predicts DelveInsight | Key Companies in the Market &#8211; Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, XWPharma, Takeda Pharmaceutical The excessive daytime sleepiness market is expected to grow due to factors like an [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":17926,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/dbcddd65-71dd-4559-8875-ae89ac4f96db","fifu_image_alt":"","footnotes":""},"categories":[11],"tags":[],"class_list":["post-17925","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/17925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/comments?post=17925"}],"version-history":[{"count":0,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/17925\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/media\/17926"}],"wp:attachment":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/media?parent=17925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/categories?post=17925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/tags?post=17925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}